FATE

Fate Therapeutics, Inc. - Common Stock

$7.45 +$0.27 +3.62%



Shares Bought1
Shares Sold1
Total2
Shares Owned0
Last Price$7.45
Total Return-$0.15
Range Today$7.09 - $7.40
52 Week Range$2.52 - $7.40
Open$7.15
Market Cap$305.54M
Volume/Average225.51K/342.73K
P/E Ratio-
Dividend/Yield-




Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. The company products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. Fate Therapeutics was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.


Open Positions

Buy Date Buy Price Quote Return $ Return % Owners

Closed Positions

Buy Date Sell Date Buy Price Sell Price Return $ Return % Owners
17-12-08 22:17 17-12-15 16:20 $4.40 $4.25 -$0.15 -3.41% funkmasterflexion elliotrr